Sorrento Therapeutics Inc
OTC:SRNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Uniparts India Ltd
NSE:UNIPARTS
|
IN |
|
K
|
Konndor Industries Ltd
BSE:532397
|
IN |
|
S
|
Shaanxi Lighte Optoelectronics Material Co Ltd
SSE:688150
|
CN |
|
Vytrus Biotech SA
MAD:VYT
|
ES |
|
Aksa Akrilik Kimya Sanayii AS
IST:AKSA.E
|
TR |
|
Mishtann Foods Ltd
BSE:539594
|
IN |
|
J
|
John Menzies PLC
XBER:B3N
|
UK |
|
Zecotek Photonics Inc
OTC:ZMSPF
|
CA |
Sorrento Therapeutics Inc
Research & Development
Sorrento Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sorrento Therapeutics Inc
OTC:SRNE
|
Research & Development
-$186.1m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-39%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Research & Development
-$523m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Sorrento Therapeutics Inc
Glance View
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The firm's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. Sorrento's immuno-oncology platforms include key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.
See Also
What is Sorrento Therapeutics Inc's Research & Development?
Research & Development
-186.1m
USD
Based on the financial report for Jun 30, 2023, Sorrento Therapeutics Inc's Research & Development amounts to -186.1m USD.
What is Sorrento Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-39%
Over the last year, the Research & Development growth was 24%. The average annual Research & Development growth rates for Sorrento Therapeutics Inc have been -20% over the past three years , -16% over the past five years , and -39% over the past ten years .
